The legal library gives you easy access to the FTC’s case information and other official legal, policy, and guidance documents.
20010594: Cox Enterprises, Inc.; Radio One, Inc.
20010588: Software AG; Saga Systems, Inc.
20010557: F. Sheridan Garrisson; FedEx Corporation
20010556: FedEx Corporation; American Freightways Corporation
20010550: Munich Re; Loews Corporation
20010548: Sheldahl, Inc.; Morgenthaler Venture Partners V, L.P.
20010546: Dover Corporation; RailAmerica, Inc.
20010508: Fresenius AG; Everest Healthcare Services Corporation
20010499: Paul G. Allen; One-on-One Sports, Inc.
20010489: InterWest Partners V, L.P.; Corixa Corporation
20010655: Pitney Bowes, Inc.; Royal Dutch Petroleum Company
20010653: Smith International, Inc.; Emerson Electric Co.
20010651: Andrew J. McKelvey; SPEC Group Holdings, Inc.
20010649: Broadcom Corporation; SiByte, Inc.
20010647: Investor AB; Molecular Staging Inc.
20010645: Computershare Limited; Merrill Lynch & Co., Inc.
Mylan Laboratories, Inc., Cambrex Corporation, Profarmaco S.R.I., and Gyma Laboratories of America, Inc.
Complaint filed in the U.S. District Court for the District of Columbia charged Mylan with restraint of trade, monopolization and conspiracy to monopolize the market for two generic drugs used to treat anxiety, lorazepam and clorazepate, through exclusive dealing arrangements. The Commission alleged that Mylan, Gyma Laboratories of America, Inc., Cambrex Corporation and Profarmaco S.R.L. conspired to deny Mylan’s competitors ingredients necessary to manufacture lorazepam and 40 clorazepate. The complaint sought consumer redress of at least $120 million and to enjoin the alleged illegal exclusive licensing agreements. The district court upheld the Commission’s authority to seek restitution in antitrust injunction actions under Section 13(b). The Commission approved a $100 million settlement. The opinion settled Commission concerns that Mylan, Gyma Laboratories of America, Inc., Cambrex Corporation and Profarmaco S.R.L. conspired to deny Mylan’s competitors ingredients necessary to manufacture lorazepam and 40 clorazepate. On Feburary 1, 2002, the court granted approval to a plan of distribution to injured consumers who paid the increased prices and state agencies, including Medicaid programs, that purchased the drugs while the illegal agreements were in effect. The funds were distributed by the states.